SF3B1 and myelodysplastic syndrome: Next, we analyzed the effect of high-risk genetic mutations for the progression of myelodysplastic syndrome to AML [26], that is, wild type SF3B1 or mutations in SRSF2, RUNX1, U2AF1, ASXL1, and TP53, on the survival outcomes in the MF cohort (Figure 4).